$73.02 Million in Sales Expected for Healthequity Inc (HQY) This Quarter

Analysts expect that Healthequity Inc (NASDAQ:HQY) will post sales of $73.02 million for the current fiscal quarter, according to Zacks Investment Research. Eight analysts have made estimates for Healthequity’s earnings, with the lowest sales estimate coming in at $71.47 million and the highest estimate coming in at $74.37 million. Healthequity posted sales of $60.44 million in the same quarter last year, which suggests a positive year-over-year growth rate of 20.8%. The business is scheduled to report its next earnings report on Monday, March 18th.

On average, analysts expect that Healthequity will report full year sales of $284.33 million for the current year, with estimates ranging from $282.94 million to $285.84 million. For the next financial year, analysts forecast that the firm will post sales of $341.29 million, with estimates ranging from $322.70 million to $349.00 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side analysts that follow Healthequity.

Healthequity (NASDAQ:HQY) last issued its earnings results on Tuesday, December 4th. The company reported $0.22 EPS for the quarter, topping the consensus estimate of $0.20 by $0.02. The firm had revenue of $70.50 million during the quarter, compared to analysts’ expectations of $69.60 million. Healthequity had a return on equity of 12.42% and a net margin of 24.52%. Healthequity’s quarterly revenue was up 24.1% compared to the same quarter last year. During the same period last year, the business earned $0.17 earnings per share.

A number of brokerages have issued reports on HQY. ValuEngine cut Healthequity from a “buy” rating to a “hold” rating in a report on Saturday, December 15th. Zacks Investment Research cut Healthequity from a “buy” rating to a “hold” rating in a report on Tuesday, December 18th. BidaskClub upgraded Healthequity from a “hold” rating to a “buy” rating in a research note on Saturday, December 1st. Finally, Cantor Fitzgerald lifted their price objective on Healthequity from $80.00 to $82.00 and gave the stock a “neutral” rating in a research report on Thursday, December 6th. One analyst has rated the stock with a sell rating, four have issued a hold rating and ten have given a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $90.15.

In related news, VP Darcy G. Mott sold 4,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 20th. The stock was sold at an average price of $76.91, for a total transaction of $307,640.00. Following the completion of the sale, the vice president now owns 89,500 shares of the company’s stock, valued at $6,883,445. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Frank Corvino sold 1,778 shares of the firm’s stock in a transaction that occurred on Monday, December 10th. The stock was sold at an average price of $67.78, for a total value of $120,512.84. Following the sale, the director now directly owns 5,051 shares of the company’s stock, valued at approximately $342,356.78. The disclosure for this sale can be found here. In the last three months, insiders sold 11,846 shares of company stock valued at $815,708. Insiders own 4.00% of the company’s stock.

A number of large investors have recently made changes to their positions in the business. Legacy Financial Advisors Inc. bought a new stake in Healthequity during the fourth quarter worth $28,000. Meeder Asset Management Inc. purchased a new position in Healthequity during the third quarter worth about $172,000. Cerebellum GP LLC bought a new stake in Healthequity during the third quarter worth about $185,000. Advisors Asset Management Inc. lifted its stake in shares of Healthequity by 57.4% in the 2nd quarter. Advisors Asset Management Inc. now owns 2,136 shares of the company’s stock valued at $160,000 after acquiring an additional 779 shares during the last quarter. Finally, Cambridge Investment Research Advisors Inc. bought a new stake in shares of Healthequity in the 3rd quarter valued at about $210,000. Institutional investors and hedge funds own 92.31% of the company’s stock.

Shares of HQY stock opened at $61.19 on Thursday. The firm has a market capitalization of $3.82 billion, a P/E ratio of 113.31, a PEG ratio of 2.35 and a beta of 1.78. Healthequity has a one year low of $47.23 and a one year high of $101.58.

Healthequity Company Profile

HealthEquity, Inc provides various solutions for managing health care accounts, health reimbursement arrangements, and flexible spending accounts for health plans, insurance companies, and third-party administrators in the United States. The company offers healthcare saving and spending platform, a cloud-based platform for individuals to make health saving and spending decisions, pay healthcare bills, compare treatment options and prices, receive personalized benefit and clinical information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.

Read More: How is inflation measured?

Get a free copy of the Zacks research report on Healthequity (HQY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Healthequity (NASDAQ:HQY)

Receive News & Ratings for Healthequity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Healthequity and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply